Expertise in
44
conditions

Dr. Nicholas J. Farrell

Hematology Oncology
6420 Rockledge Drive, Suite 4200, Suite 4200, 
Bethesda, MD 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
44
conditions
6420 Rockledge Drive, Suite 4200, Suite 4200, 
Bethesda, MD 

Overview

Nicholas Farrell is a Hematologist Oncology provider practicing medicine in Bethesda, Maryland.

Dr. Farrell is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Iron Deficiency Anemia.

Dr. Farrell is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 6 clinical trials. Dr. Farrell is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in MD

Board Certifications

American Board Of Internal Medicine

Fellowships

Virginia Commonwealth University School of Medicine, Hematology and Oncology, 2008

Hospital Affiliations

Suburban Hospital
Holy Cross Germantown Hospital
Adventist Healthcare Shady Grove Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Maryland Oncology Hematology PA
6420 Rockledge Drive, Suite 4200, Suite 4200, Bethesda, MD 20817

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib
An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Drug
Study Phase: Phase 4
A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: February 09, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

4 Total Publications

Transdermal microneedles for the programmable burst release of multiple vaccine payloads.
Transdermal microneedles for the programmable burst release of multiple vaccine payloads.
Journal: Nature biomedical engineering
Published: April 15, 2019
Similar Doctors
Expertise in
32
conditions
Dr. Maria R. Baer
Hematology Oncology | Oncology
Expertise in
32
conditions
Dr. Maria R. Baer
Hematology Oncology | Oncology
Referral may be required

Stoler Outpatient Cancer Clinic

22 South Greene Street, Floor 1, 
Baltimore, MD 
 (34.7 miles away)
410-328-7609
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Maria Baer is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Baer is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Splenectomy. Dr. Baer is board certified in American Board Of Internal Medicine - Hematology, 1984 and American Board Of Internal Medicine - Internal Medicine, 1983. Dr. Baer is currently accepting new patients.

Expertise in
36
conditions
Dr. Ralph V. Boccia
Hematology Oncology | Oncology
Expertise in
36
conditions
Dr. Ralph V. Boccia
Hematology Oncology | Oncology
Referral may be required
Before you request

The Center For Cancer & Blood Disorders

6410 Rockledge Drive, Suite 660, Suite 660, 
Bethesda, MD 
 (0.1 miles away)
301-571-0019
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Ralph V. Boccia is a hematologist affiliated with Sibley Memorial Hospital, Suburban Hospital, Shady Grove Adventist Hospital, Holy Cross Hospital and MedStar Georgetown University Hospital, where he is a clinical associate professor of medicine for the University, as well as the medical director of the International Oncology Network (ION) Clinical Research Program and the chairman of ION’s Medical Advisory Panel. He practices out of the Center for Cancer and Blood Disorders, of which he is the founder and medical director, located in Bethesda, Maryland and Germantown, Maryland. Dr. Boccia earned his medical degree from the Autonomous University of Guadalajara School of Medicine. He completed a residency in internal medicine at Kern Medical Center, followed by a fellowship in hematology, oncology and bone marrow transplant at the combined UCLA-Veterans Administration Program and The National Cancer Institute at the National Institutes of Health. Dr. Boccia is a member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. Dr. Boccia has been listed as a Top Doctor by Washingtonian Magazine and Consumers’ Checkbook Magazine since 1992. He has also been recognized as a Super Doctor by The Washington Post Magazine and a Regional Top Doctor for Washington, D.C., Baltimore and Washington-Baltimore by Castle Connolly. Dr. Boccia has contributed to various articles with his research, published in journals such as Annals of Internal Medicine, Journal of Clinical Oncology and The Lancet. Recent News Articles and Media Coverage Bladder cancer trends in Montgomery and Prince George's counties: Welcome news - and 3 facts you need to know. NJ.com (08/16/2016) RCCA Expands to Maryland to Become One of the Nation's First Multi-State Oncology/Hematology Physician-Owned and -Operated Networks. OncLive (10/06/2015). Dr. Boccia is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Bone Tumor, Anemia, Iron Deficiency Anemia, Multiple Myeloma, and Splenectomy. Dr. Boccia is board certified in American Board Of Internal Medicine. Dr. Boccia is currently accepting new patients.

Expertise in
28
conditions
Dr. Aaron P. Rapoport
Hematology Oncology | Oncology
Expertise in
28
conditions
Dr. Aaron P. Rapoport
Hematology Oncology | Oncology
Referral may be required

Stoler Outpatient Cancer Clinic

22 South Greene Street, Floor 1, 
Baltimore, MD 
 (34.7 miles away)
410-328-7609
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Rapoport is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Rapoport is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is board certified in American Board Of Internal Medicine - Internal Medicine, 1989 and American Board Of Internal Medicine - Hematology, 1992. Dr. Rapoport is currently accepting new patients.

Frequently Asked Questions about Dr. Nicholas J. Farrell

How do I make an appointment with Dr. Nicholas J. Farrell?

You can book an appointment with Dr. Nicholas J. Farrell by calling their office at 301-929-0765. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nicholas J. Farrell a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nicholas J. Farrell is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nicholas J. Farrell specialize in?

While Dr. Nicholas J. Farrell is a Hematology Oncology, they have specific expertise in Lung Cancer, Childhood Iron Deficiency Anemia, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Nicholas J. Farrell participate in research or clinical trials?

Yes. Dr. Nicholas J. Farrell has published 4 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Nicholas J. Farrell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nicholas J. Farrell accept my insurance?

Dr. Nicholas J. Farrell accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 301-929-0765 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farrell's expertise for a condition
ConditionClose
    View All 40 Advanced Conditions
    View All 144 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile